Literature DB >> 23689884

Vaccination for the control of Rift Valley fever in enzootic and epizootic situations.

B Dungu1, M Donadeu, M Bouloy.   

Abstract

Vaccination continues to be the most effective way to control Rift Valley fever (RVF), a zoonotic insect-borne viral disease of livestock. The irregular, cyclical and persistent nature of RVF in its occurrence in enzootic situations suggests that the vaccination strategy to be considered for these regions should be different from what is envisaged for free from risk regions. Currently available RVF vaccines have been extensively used for the control of the disease. However, these vaccines have shortcomings that have encouraged many research groups to develop new vaccine candidates that would address a large number of the current challenges, and be suitable for use both in disease-free regions and in different contingency and emergency preparedness strategies. The characteristics of different RVF vaccines and vaccination strategies are discussed in this report.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689884     DOI: 10.1159/000157178

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  7 in total

Review 1.  Rift Valley fever: biology and epidemiology.

Authors:  Daniel Wright; Jeroen Kortekaas; Thomas A Bowden; George M Warimwe
Journal:  J Gen Virol       Date:  2019-07-16       Impact factor: 5.141

2.  Epidemiologic and Environmental Risk Factors of Rift Valley Fever in Southern Africa from 2008 to 2011.

Authors:  Margaret M Glancey; Assaf Anyamba; Kenneth J Linthicum
Journal:  Vector Borne Zoonotic Dis       Date:  2015-08       Impact factor: 2.133

Review 3.  Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology.

Authors:  Sarah C Gilbert; George M Warimwe
Journal:  Vaccine       Date:  2017-05-30       Impact factor: 3.641

Review 4.  Strategies to increase adoption of animal vaccines by smallholder farmers with focus on neglected diseases and marginalized populations.

Authors:  Meritxell Donadeu; Nick Nwankpa; Bernadette Abela-Ridder; Baptiste Dungu
Journal:  PLoS Negl Trop Dis       Date:  2019-02-07

5.  Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle.

Authors:  Pawan Dulal; Daniel Wright; Rebecca Ashfield; Adrian V S Hill; Bryan Charleston; George M Warimwe
Journal:  Vaccine       Date:  2016-03-25       Impact factor: 3.641

6.  Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever.

Authors:  George M Warimwe; Joseph Gesharisha; B Veronica Carr; Simeon Otieno; Kennedy Otingah; Danny Wright; Bryan Charleston; Edward Okoth; Lopez-Gil Elena; Gema Lorenzo; El-Behiry Ayman; Naif K Alharbi; Musaad A Al-dubaib; Alejandro Brun; Sarah C Gilbert; Vishvanath Nene; Adrian V S Hill
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

7.  Safety and immunogenicity of Onderstepoort Biological Products' Rift Valley fever Clone 13 vaccine in sheep and goats under field conditions in Senegal.

Authors:  Modou M Lo; Victor Mbao; Pascale Sierra; Yaya Thiongane; Mariame Diop; Meritxell Donadeu; Baptiste Dungu
Journal:  Onderstepoort J Vet Res       Date:  2015-05-29       Impact factor: 1.792

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.